Cycle Pharmaceuticals and the Cystic Fibrosis Trust partnering to explore a new antibacterial option for people with cystic fibrosis.
Cycle Pharmaceuticals and the Cystic Fibrosis Trust have launched a new project to investigate the repurposing of an existing pharmaceutical drug for a new use: the management of pulmonary infections due to Pseudomonas aeruginosa in people with cystic fibrosis. The project is being led by Professor Jane Davies at Imperial College, London.
Cystic fibrosis (CF) is an inherited disease in which there is an accumulation of thick mucus in the lungs that allows bacteria to grow more easily, causing infections. Pseudomonas aeruginosa is a frequent cause of lung infections in cystic fibrosis patients. Whilst there are antibiotics approved to treat CF lung infections, these are limited in their effectiveness.
One significant issue is the emergence of antimicrobial resistance; for people with cystic fibrosis this is a matter of life and death. The thick mucus in lungs affected by cystic fibrosis harbour bugs that once caught, can remain in the lungs for years. For those where chronic or long term bacterial infections occur, bacterial resistance to antibiotics makes treatment less effective. As bugs become resistant to standard antibiotics, doctors are forced to prescribe older and rarely used antibiotics, which are less effective and have serious side effects. As such, there is an important need to explore new routes to fight bugs such as Pseudomonas aeruginosa in cystic fibrosis.
Dr Keith Brownlee, Director of Impact at the Cystic Fibrosis Trust added: “New treatment options are desperately needed and we’re delighted to be investing over £25,000 in this partnership. We are hopeful that the results of this research will bring more options to the treatment of Pseudomonas aeruginosa and as such, improve the lives of people living with cystic fibrosis.”
James Harrison, Executive Chairman of Cycle Pharmaceuticals, commented: “We are very pleased to be working alongside the Cystic Fibrosis Trust on this exciting project. We consider the Cystic Fibrosis Trust to be a model patient advocacy group. Our joint development work is already well underway.”
Antonio Benedetti, CEO of Cycle Pharmaceuticals, added: “This project underlines our commitment to try to improve the drug treatments taken by rare disease patients. If the project is successful, we will look to commence clinical trials as soon as practical.”